EN DE
Watch Cutia Therapeutics for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cutia Therapeutics (2487) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Cutia Therapeutics stock HK$0.89, price HK$0.68, upside +31.4%, quality 41 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

CT Cutia Therapeutics logo Thin data Nov 10, 2026

Cutia Therapeutics

2487 · HK

Cheap enough by our rule, but weak company and falling price: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Fair value HK$0.8938 · Fairly valued 
Quality 41/100 
Expensive Growth (revenue 3y +209.2 %/yr in CNY) 
Mixed vs. peers (4/9) 
Falling price (downtrend) 
Loss-making · -84.6% net margin (TTM) 
Negative free cash flow 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch Cutia Therapeutics for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$30.90 HK$0.6700 Fair Value HK$0.8938 Jun 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

41‑month range HK$0.6700 – HK$30.90 · fair‑value band HK$0.6703 – HK$1.12 · the HK$0.6800 price screens below the HK$0.8938 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Cutia Therapeutics in your weekly email

Every Wednesday you see whether Cutia Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People's Republic of China and Hong Kong.

Show moreShow less

It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication.

The company provides CU-40102, a topical finasteride spray for androgenetic alopecia treatment; and CU-10201, a topical 4% minocycline foam for acne vulgaris treatment.

It is also involved in the development of CU-20401, a recombinant mutant collagenase, currently under Phase II clinical trial for submental adipose accumulation (submental fat); CU-40101, a topical small molecule thyroid hormone receptor agonist liniment, currently completed Phase I clinical trial for the treatment of androgenetic alopecia; and CU-30101, a localized topical lidocaine and tetracaine compound topical anesthesia cream, completed Phase III clinical trial for surface dermatologic operations.

In addition, the company provides CATAME, a technology platform that enables the development of a wide range of product dosage forms and the relevant formulation technology.

Further, it offers product pipeline of creams, sprays, ointments, aerosol foams and other dosage forms through the CATAME platform. The company was incorporated in 2019 and is headquartered in Shanghai, China.

Stock analysis

Cutia Therapeutics (2487) currently trades at HK$0.6800, while our estimate is HK$0.8938, so the stock looks roughly fairly valued today (gap 23.9%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.6703 (bear) to HK$1.12 (bull), the price of HK$0.6800 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Cutia Therapeutics reported revenue of 336M CNY in FY2025 versus 2.0M CNY in FY2021, a compound +258.4%/yr. Reported net income was −340M CNY in FY2025.

Key figures

Market cap HK$253M (≈ $32.3M) Micro · P/S ratio 0.81 · Net margin −101% · Return on equity −38.3% · Return on assets (EBIT) −24.3% (5-year average) · Operating margin −235% · Revenue (TTM) 333M CNY · Revenue growth (YoY) −5.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 91% below its 52-week high and 1% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 31%, 2487 screens cheaper than that median.

Fair Value

Bear HK$0.6703 Fair Value HK$0.8938 Bull HK$1.12
Price HK$0.6800 · Upside +31.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 93
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 39
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 10
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+20.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+209.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8,831.5% (2021) → −91.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 2487, get fair value alerts →

Compare Cutia Therapeutics with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Above median
Fair Value upside +31.4% · Top 25%
Profitability
Return on assets −26.0% · Below median
Net margin (12 months) −84.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −5.4% · Below median
Balance sheet
Debt / equity 0.10× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.24× · Cheapest 25%
P/S (12 months) 0.65× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)75 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 2487
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 2487
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs 2487
Genmab A/S GMAB kr 3,448 kr 3,793 +10% vs 2487
argenx SE ARGX $960.04 $908.40 −5% vs 2487
CSL Limited CSL A$202.52 A$185.51 −8% vs 2487
Moderna, Inc MRNA $223.37 $139.99 −37% vs 2487
Revolution Medicines, Inc RVMD $172.29 $88.78 −48% vs 2487
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 2487
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 2487

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cutia Therapeutics: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cutia Therapeutics Fair Value". https://www.fairvalue-calculator.com/stock/2487

Frequently asked questions

Is Cutia Therapeutics (2487) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.8938 versus a price of HK$0.6800, about +31% upside (fairly valued).
What is the fair value of 2487?
Our estimate for Cutia Therapeutics is HK$0.8938 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.6800.
What is the quality score of 2487?
Cutia Therapeutics has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cutia Therapeutics (2487)?
Our calculated price target is the estimate of HK$0.8938 (as of Nov 10, 2026). Cautious scenario HK$0.6703, optimistic scenario HK$1.12. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cutia Therapeutics stock forecast for 2026?
Our estimate puts fair value at HK$0.8938, about +31% upside versus a price of HK$0.6800 (fairly valued). Cautious scenario HK$0.6703, optimistic scenario HK$1.12. The calculation is refreshed regularly with new filings.
What is the revenue of Cutia Therapeutics (2487)?
Cutia Therapeutics reported trailing-twelve-month revenue of about 333M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Cutia Therapeutics (2487)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cutia Therapeutics it is HK$0.8938 per share (as of Nov 10, 2026), against a price of HK$0.6800.
Is Cutia Therapeutics stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2487 trades below its calculated fair value: price HK$0.6800, fair value HK$0.8938, a gap of about +31% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2487?
No. The price is what the market pays today (HK$0.6800); the fair value is what the company's own numbers justify (HK$0.8938). For Cutia Therapeutics the two are HK$0.2138 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cutia Therapeutics worth?
The market values Cutia Therapeutics at about HK$253M (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.6800; our models calculate a fair value of HK$0.8938 per share.
What do the bullish and bearish scenarios say about 2487?
Our models span a range for Cutia Therapeutics: cautious scenario HK$0.6703, base HK$0.8938, optimistic HK$1.12 per share (as of Nov 10, 2026, price HK$0.6800). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cutia Therapeutics (2487)?
Balance-sheet figures for Cutia Therapeutics (as of Nov 10, 2026): return on equity −38.3%, debt of 0.10 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 2487 from its 52-week high?
Cutia Therapeutics trades at HK$0.6800, about 91% below its 52-week high of HK$7.16 and 1% above the low of HK$0.6700 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.8938 is for.
Which stocks are comparable to Cutia Therapeutics?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cutia Therapeutics stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.6800, calculated fair value HK$0.8938 (+31%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Cutia Therapeutics currently trades 24% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cutia Therapeutics (2487)?
The closing price on Nov 13, 2026 was HK$0.6800. Our estimate is HK$0.8938, about +31% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cutia Therapeutics right now?
The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Cutia Therapeutics

How large is the market capitalisation of Cutia Therapeutics (2487)?
The market capitalisation of Cutia Therapeutics is HK$253M (≈ $32.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cutia Therapeutics (2487)?
The price-to-sales ratio of Cutia Therapeutics is 0.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Cutia Therapeutics (2487)?
The net margin of Cutia Therapeutics is −101% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cutia Therapeutics (2487)?
The return on equity (ROE) of Cutia Therapeutics is −38.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cutia Therapeutics (2487)?
On an EBIT basis the return on assets of Cutia Therapeutics is −24.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cutia Therapeutics (2487)?
The operating margin of Cutia Therapeutics is −235% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cutia Therapeutics (2487)?
Revenue at Cutia Therapeutics is down 5.4% versus a year earlier (3y avg +209%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cutia Therapeutics (2487) generate?
The free cash flow of Cutia Therapeutics is −303M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cutia Therapeutics (2487) carry?
The net debt of Cutia Therapeutics is 51.8M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cutia Therapeutics in the live analysis

One click puts Cutia Therapeutics on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.